CHMP Gives Positive Opinion to Vertex’s Triple Combination Therapy Kaftrio
The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Kaftrio (ivacaftor/tezacaftor/elexacaftor) in...
Kalydeco Approved in Europe to Treat Children with R117H Mutation
The European Commission has approved Vertex’s Kalydeco (ivacaftor) for the treatment of children and adolescents with cystic fibrosis...
Real-world Use of Kalydeco for CF Highly Effective, Large-scale Analysis Shows
Kalydeco treatment led to fewer deaths, transplants, hospitalizations, and exacerbations in people with cystic fibrosis (CF) compared to...
Pharmac funds new cystic fibrosis medicine
New treatment for cystic fibrosis is on the horizon, one that will help young children suffering from the disorder digest their food more...
Vertex Announces Availability of Cystic Fibrosis Medicine KALYDECO® (ivacaftor) in New Zealand
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that KALYDECO® (ivacaftor) will be available to eligible patients with...
New Vertex cystic fibrosis drug approved, extending treatments to 90% of patients
Vertex Pharmaceuticals on Monday won approval for its fourth treatment for cystic fibrosis, a combination drug that extends a new form of...